Cargando…

Quantitative benefit-risk assessment of methylprednisolone in multiple sclerosis relapses

BACKGROUND: High-dose short-term methylprednisolone is the recommended treatment in the management of multiple sclerosis relapses, although it has been suggested that lower doses may be equally effective. Also, glucocorticoids are associated with multiple and often dose-dependent adverse effects. Th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Caster, Ola, Edwards, I. Ralph
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4609048/ https://www.ncbi.nlm.nih.gov/pubmed/26475456 http://dx.doi.org/10.1186/s12883-015-0450-x

Ejemplares similares

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Computing limits on medicine risks based on collections of individual case reports
por: Caster, Ola, et al.
Publicado: (2014)

Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis
por: Lugaresi, Alessandra, et al.
Publicado: (2013)

Oral versus intravenous methylprednisolone for the treatment of multiple sclerosis relapses: A meta-analysis of randomized controlled trials
por: Liu, Shuo, et al.
Publicado: (2017)

Mild COVID-19 symptoms despite treatment with teriflunomide and high-dose methylprednisolone due to multiple sclerosis relapse
por: Möhn, Nora, et al.
Publicado: (2020)

Monthly intravenous methylprednisolone in relapsing-remitting multiple sclerosis - reduction of enhancing lesions, T2 lesion volume and plasma prolactin concentrations
por: Then Bergh, Florian, et al.
Publicado: (2006)

Methylprednisolone/tozinameran: Multiple sclerosis and lack of efficacy: case report
Publicado: (2022)

Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients
por: Nociti, Viviana, et al.
Publicado: (2018)

Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response
por: Evangelopoulos, Maria Eleftheria, et al.
Publicado: (2021)

Hepatotoxicity after high‐dose intravenous methylprednisolone in multiple sclerosis patients
por: Hidalgo de la Cruz, Milagros, et al.
Publicado: (2017)

Benefit–Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis
por: Comi, Giancarlo, et al.
Publicado: (2017)

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis
por: Vališ, Martin, et al.
Publicado: (2023)

Cognition During and After Multiple Sclerosis Relapse as Assessed With the Brief International Cognitive Assessment for Multiple Sclerosis
por: Giedraitiene, Natasa, et al.
Publicado: (2018)

Protocol for a Cross-Sectional Study: Effects of a Multiple Sclerosis Relapse Therapy With Methylprednisolone on Offspring Neurocognitive Development and Behavior (MS-Children)
por: Kozik, Valeska, et al.
Publicado: (2022)

Myelin basic protein expression in thymoma after methylprednisolone administration for multiple sclerosis
por: Isono, Tomomi, et al.
Publicado: (2021)

Assessing disability and relapses in multiple sclerosis on tele-neurology
por: Moccia, Marcello, et al.
Publicado: (2020)

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis
por: Brochet, Bruno, et al.
Publicado: (2017)

Author Correction: Methylprednisolone stimulated gene expression (GILZ, MCL-1) and basal cortisol levels in multiple sclerosis patients in relapse are associated with clinical response
por: Evangelopoulos, Maria Eleftheria, et al.
Publicado: (2021)

Erratum: Protocol for a cross-sectional study: effects of a multiple sclerosis relapse therapy with methylprednisolone on offspring neurocognitive development and behavior (MS-children)
Publicado: (2023)

Quantitative Determination of Regional Lesion Volume and Distribution in Children and Adults with Relapsing-Remitting Multiple Sclerosis
por: Ghassemi, Rezwan, et al.
Publicado: (2014)

Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse
por: Jongen, Peter Joseph, et al.
Publicado: (2016)

Venous Thrombosis in Multiple Sclerosis Patients after High-Dose Intravenous Methylprednisolone: The Preventive Effect of Enoxaparin
por: Kalanie, Hossein, et al.
Publicado: (2011)

Quantitative Assessment of Finger Motor Impairment in Multiple Sclerosis
por: Bonzano, Laura, et al.
Publicado: (2013)

Cost Assessment Modelling of Treatments for Highly Active Relapsing Multiple Sclerosis
por: Mankinen, Petri, et al.
Publicado: (2019)

Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development Program
por: Havrdova, Eva, et al.
Publicado: (2017)

T Cell Vaccination Benefits Relapsing Progressive Multiple Sclerosis Patients: A Randomized, Double-Blind Clinical Trial
por: Karussis, Dimitrios, et al.
Publicado: (2012)

Biochemical Differences in Cerebrospinal Fluid between Secondary Progressive and Relapsing–Remitting Multiple Sclerosis
por: Herman, Stephanie, et al.
Publicado: (2019)

Factors Involved in Relapse of Multiple Sclerosis
por: Kamel, Fatemah Omar
Publicado: (2019)

Current Safety Concerns with Human Papillomavirus Vaccine: A Cluster Analysis of Reports in VigiBase(®)
por: Chandler, Rebecca E., et al.
Publicado: (2016)

Quantitative electroencephalography reveals different physiological profiles between benign and remitting-relapsing multiple sclerosis patients
por: Vazquez-Marrufo, Manuel, et al.
Publicado: (2008)

Methylprednisolone-Induced Symptomatic Sinus Bradycardia in a Multiple Sclerosis Patient: A Case Report
por: Miqdad, Mohammed A, et al.
Publicado: (2022)

The Lived Experience of Multiple Sclerosis Relapse: How Adults with Multiple Sclerosis Processed Their Relapse Experience and Evaluated Their Need for Postrelapse Care
por: Asano, Miho, et al.
Publicado: (2015)

Predictors of severity and outcome of multiple sclerosis relapses
por: Hosny, Hassan Saad, et al.
Publicado: (2023)

Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)

A novel prognostic score to assess the risk of progression in relapsing−remitting multiple sclerosis patients
por: Pisani, Anna Isabella, et al.
Publicado: (2021)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Seasonal variation in multiple sclerosis relapse
por: Harding, Katharine, et al.
Publicado: (2017)

Osteopontin Is Associated with Multiple Sclerosis Relapses
por: Stampanoni Bassi, Mario, et al.
Publicado: (2023)

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
por: Singer, Barry A.
Publicado: (2017)

Risk knowledge of people with relapsing-remitting multiple sclerosis – Results of an international survey
por: Giordano, Andrea, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_vgqjj3krigefsnpff41j9lbe5n